目的 探讨沥水调脂胶囊联合瑞舒伐他汀钙片治疗儿童高脂血症的临床疗效。方法 选取2019年2月-2020年11月开封市儿童医院收治的132例高脂血症患儿作为研究对象，对所有患儿根据随机数字表法分为对照组和治疗组，每组各66例。对照组口服瑞舒伐他汀钙片，10 mg/次，1次/d。治疗组在对照组基础上口服沥水调脂胶囊，3粒/次，3次/d。两组连续治疗8周。观察两组的治疗效果，比较两组患儿的血脂指标、载脂蛋白和血清炎症因子水平。结果 治疗后，治疗组的总有效率为90.91%，对照组的总有效率为77.27%，组间比较有明显差异（P<0.05）。治疗后，两组的总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、TC-HDL-C/高密度脂蛋白胆固醇（HDL-C）均显著降低（P<0.05），以治疗组TC、TG、LDL-C、TC-HDL-C/HDL-C降低更明显（P<0.05）。治疗后，两组的载脂蛋白AI（ApoAI）、载脂蛋白B（ApoB）、ApoB/ApoAI明显下降，差异有统计学意义（P<0.05）；治疗组的ApoAI、ApoB、ApoB/ApoAI比对照组低，差异有统计学意义（P<0.05）。治疗后，两组的C反应蛋白（CRP）、白细胞介素-6（IL-6）、细胞间黏附分子-1（ICAM-1）水平显著降低，差异有统计学意义（P<0.05）；治疗后治疗组的CRP、IL-6、ICAM-1水平比对照组低，差异具有统计学意义（P<0.05）。结论 沥水调脂胶囊联合瑞舒伐他汀钙片治疗小儿高脂血症的疗效确切，可调节载脂蛋白，降低血脂水平和炎症反应，且药物安全性良好。

Objective To investigate the clinical efficacy of Lishui Tiaozhi Capsules combined with Rosuvastatin Calcium Tablets in treatment of hyperlipidemia in children. Methods Children (122 cases) with hyperlipidemia in Kaifeng Children's Hospital from February 2019 to February 2020 were divided into control and treatment groups according to the random number table method, and each group had 66 cases. Children in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily. Children in the treatment group were po administered with Lishui Tiaozhi Capsules on the basis of the control group, 3 grains/time, three times daily. Children in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the blood lipid index, apolipoprotein, and serum inflammatory index in two groups were compared. Results After treatment, the total effective rate was 90.91% in the treatment group, and 77.27% in the control group, and there was significant difference between two groups (P<0.05). After treatment, the TC, TG, LDL-C, and TC-HDL-C/HDL-C in two groups were significantly decreased (P<0.05), and the TC, TG, LDL-C, and TC-HDL-C/HDL-C in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the ApoAI, ApoB, and ApoB/ApoAI of two groups were significantly decreased (P<0.05). The ApoAI, ApoB, and ApoB/ApoAI in the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of the CRP, IL-6, and ICAM-1 in two groups were significantly decreased (P<0.05). After treatment, the levels of CRP, IL-6, and ICAM-1 in the treatment group were lower than those in the control group (P<0.05). Conclusion Lishui Tiaozhi Capsules combined with Rosuvastatin Calcium Tablets is effective in the treatment of hyperlipidemia in children, can regulate apolipoprotein, reduce blood lipid level, and inflammatory reaction, with good safety.

R973

河南省医学科技攻关计划项目（2018020856）